VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

CEO

Mr. Jeffery R. Baxter FCMA

Karyawan

131

Negara

Kanada

ISIN

CA91822J1030

Pencatatan

STU

LO91.STU

0 Comments

Bagikan pendapatmu

FAQ

Apa simbol saham VBI Vaccines?▼

Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa Boerse Stuttgart, saham VBI Vaccines diperdagangkan dengan simbol LO91.STU.

Apakah VBI Vaccines membayar dividen?▼

Ya, dividen LO91.STU dibayarkan tahunan. Dividen terakhir per saham adalah 17,02 EUR. Per hari ini, Dividend Yield (FWD)% adalah 0%.

Berapa jumlah karyawan VBI Vaccines?▼

Per Juli 27, 2026, perusahaan memiliki 131 karyawan.

VBI Vaccines berada di sektor apa?▼

VBI Vaccines beroperasi di sektor Kesehatan & Kebugaran.

Kapan VBI Vaccines menyelesaikan split saham?▼

Pemecahan saham terakhir VBI Vaccines terjadi pada April 12, 2023 dengan rasio 1:30.

Di mana kantor pusat VBI Vaccines?▼

Kantor pusat VBI Vaccines berlokasi di Cambridge, Kanada.